Hospital
Rhode Island Hospital
Rhode Island Hospital was paid $380.77M by Medicaid between Jan 2018 and Dec 2024, across 667 billing codes. Its largest line is G0378, Hospital observation service, per hour — 5.8% of everything it billed.
33Billing provider infoRHODE ISLAND HOSPITAL
PROVIDENCE, RI 02903
PROVIDENCE, RI 02903
33aNPI1588659528assigned 09/15/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$380.77M
24GClaims2,167,654
24DCodes billed667
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Rhode Island
Rank by total paid#1 of 11
Median peer was paid$12.56M
This provider vs. median30×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MARKELL, PETER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 518,483 | $74.65M | |
| 2019 | 581,234 | $108.82M | |
| 2020 | 238,156 | $45.44M | |
| 2021 | 272,370 | $45.23M | |
| 2022 | 210,911 | $36.26M | |
| 2023 | 184,931 | $36.72M | |
| 2024incomplete | 161,569 | $33.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0378 | Hospital observation service, per hour | 5.8% | 10,050 | 8,149 | $22.20M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.6% | 24,695 | 21,069 | $21.21M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.4% | 34,990 | 30,650 | $20.73M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.7% | 53,269 | 45,169 | $17.87M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 4.2% | 3,819 | 3,148 | $15.86M |
| 90999 | Dialysis (unlisted procedure)Unlisted dialysis procedure, inpatient or outpatient | 2.7% | 11,754 | 802 | $10.39M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 2.1% | 7,740 | 664 | $7.89M |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 1.9% | 2,410 | 2,097 | $7.30M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.8% | 16,034 | 8,430 | $6.93M |
| J9271 | Injection, pembrolizumab, 1 mg | 1.7% | 1,116 | 663 | $6.49M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.5% | 47,354 | 37,964 | $5.83M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.4% | 4,858 | 4,045 | $5.41M |
655 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 84,047 | $5.19M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 26,034 | $5.06M |
| 77386 | 1.3% | 3,954 | $5.05M | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 1.2% | 15,952 | $4.56M |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 1.2% | 13,979 | $4.54M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 21,223 | $4.37M |
| 99213 | Doctor's office visit, returning patient (routine) | 1.1% | 46,258 | $4.28M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.1% | 2,453 | $4.25M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 34,725 | $3.41M |
| 80053 | Comprehensive metabolic panel | <1% | 37,443 | $3.40M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 22,368 | $3.39M |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,428 | $3.33M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 36,838 | $3.26M |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,685 | $3.26M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 12,285 | $3.18M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,569 | $3.18M |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 9,568 | $2.91M |
| 96367 | <1% | 7,413 | $2.83M | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,424 | $2.74M |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 32,060 | $2.74M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 38,536 | $2.70M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,336 | $2.66M |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,823 | $2.38M |
| 83735 | <1% | 20,697 | $2.06M | |
| 82248 | <1% | 27,362 | $1.99M | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,010 | $1.96M |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 12,433 | $1.93M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 4,445 | $1.90M |
| J2704 | Injection, propofol, 10 mg | <1% | 10,033 | $1.86M |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,889 | $1.81M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 6,993 | $1.76M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,531 | $1.75M |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,912 | $1.74M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 4,078 | $1.73M |
| 82948 | <1% | 17,020 | $1.70M | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,081 | $1.67M |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,441 | $1.63M |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 8,324 | $1.57M |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,494 | $1.56M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 10,134 | $1.55M |
| J3490 | Unclassified drugs | <1% | 6,177 | $1.54M |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 6,048 | $1.51M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,448 | $1.49M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,326 | $1.48M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,550 | $1.44M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,634 | $1.43M |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,681 | $1.39M |
| 96417 | <1% | 2,843 | $1.37M | |
| 84484 | <1% | 10,586 | $1.36M | |
| 85027 | <1% | 26,194 | $1.27M | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13,470 | $1.27M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,596 | $1.27M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 9,855 | $1.24M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13,321 | $1.22M |
| 85610 | <1% | 18,946 | $1.20M | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,944 | $1.20M |
| 96415 | <1% | 4,736 | $1.18M | |
| 81003 | <1% | 18,191 | $1.18M | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,999 | $1.15M |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 2,999 | $1.12M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 13,840 | $1.10M |
| 77336 | <1% | 2,544 | $1.07M | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,980 | $1.03M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13,143 | $1.01M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 13,348 | $1.00M |
| 77334 | <1% | 1,415 | $978K | |
| 83690 | <1% | 10,358 | $968K | |
| 81001 | <1% | 15,085 | $949K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,919 | $933K |
| 86850 | <1% | 11,569 | $928K | |
| 86900 | <1% | 11,748 | $915K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 45,885 | $903K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 2,459 | $898K |
| 86901 | <1% | 11,689 | $893K | |
| 84100 | <1% | 11,542 | $885K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 12,382 | $872K |
| 99205 | Prolong outpt/office vis | <1% | 3,752 | $863K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,223 | $811K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 5,679 | $809K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,846 | $798K |
| J9299 | Injection, nivolumab, 1 mg | <1% | 146 | $782K |
| 93975 | <1% | 2,891 | $782K | |
| 96376 | <1% | 6,255 | $773K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 5,652 | $761K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 266 | $758K |
| 85730 | <1% | 8,206 | $749K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 4,574 | $741K |
| 64644 | <1% | 660 | $721K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,565 | $717K |
| 97113 | <1% | 6,986 | $694K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 14,535 | $694K |
| 77300 | <1% | 849 | $691K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,869 | $686K |
| 97803 | <1% | 7,783 | $680K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 24,623 | $676K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 5,608 | $675K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 891 | $667K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 480 | $662K |
| 97802 | <1% | 4,587 | $657K | |
| 76770 | <1% | 4,648 | $655K | |
| 85007 | <1% | 12,101 | $634K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,477 | $621K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 4,258 | $620K |
| 83605 | <1% | 3,720 | $616K | |
| 96910 | <1% | 8,807 | $606K | |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | <1% | 3,512 | $593K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,945 | $584K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,309 | $581K |
| 72141 | <1% | 1,219 | $545K | |
| 74183 | <1% | 619 | $541K | |
| 82565 | <1% | 16,270 | $529K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 728 | $526K |
| 96411 | <1% | 1,204 | $524K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,658 | $517K |
| 82310 | <1% | 10,419 | $513K | |
| 80076 | <1% | 15,604 | $506K | |
| 96416 | <1% | 1,419 | $505K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,723 | $505K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 5,150 | $505K |
| 97161 | <1% | 4,317 | $502K | |
| 84703 | <1% | 5,237 | $499K | |
| 92523 | <1% | 2,078 | $496K | |
| 99218 | <1% | 2,382 | $494K | |
| 97162 | <1% | 3,560 | $486K | |
| 84520 | <1% | 14,982 | $481K | |
| 80061 | Lipid panel | <1% | 10,512 | $477K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 8,070 | $474K |
| 80051 | <1% | 10,262 | $472K | |
| 82728 | <1% | 14,123 | $469K | |
| 82805 | <1% | 2,685 | $468K | |
| 86140 | <1% | 15,203 | $463K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,280 | $460K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 6,673 | $453K |
| 80050 | General health panel | <1% | 4,766 | $450K |
| 81025 | <1% | 8,351 | $449K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,152 | $442K |
| 95782 | <1% | 264 | $422K | |
| C1769 | Guide wire | <1% | 663 | $414K |
| 72158 | <1% | 441 | $406K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,796 | $401K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,275 | $396K |
| 82947 | <1% | 4,388 | $385K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 568 | $385K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 832 | $378K |
| 77412 | <1% | 2,391 | $376K | |
| 85651 | <1% | 14,466 | $370K | |
| 36430 | <1% | 1,800 | $365K | |
| 84295 | <1% | 2,711 | $363K | |
| 94010 | <1% | 3,845 | $361K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 2,657 | $358K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,125 | $356K |
| 73610 | <1% | 5,332 | $356K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,008 | $354K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 782 | $352K |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,255 | $352K |
| 71250 | <1% | 1,681 | $348K | |
| J9312 | Injection, rituximab, 10 mg | <1% | 57 | $343K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 2,779 | $340K |
| 84132 | <1% | 2,685 | $327K | |
| 96127 | <1% | 8,377 | $323K | |
| 99152 | <1% | 1,136 | $323K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,849 | $312K |
| 84460 | <1% | 11,780 | $312K | |
| 73560 | <1% | 4,080 | $310K | |
| 72146 | <1% | 493 | $307K | |
| 83880 | <1% | 2,128 | $306K | |
| 72131 | <1% | 1,669 | $303K | |
| 94060 | <1% | 1,636 | $302K | |
| 84450 | <1% | 11,203 | $293K | |
| 93325 | <1% | 1,827 | $289K | |
| 95812 | <1% | 860 | $285K | |
| 86780 | <1% | 4,661 | $284K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,117 | $281K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,529 | $279K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,042 | $278K |
| 76536 | <1% | 2,427 | $276K | |
| 93041 | <1% | 2,931 | $273K | |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 50 | $265K |
| 90461 | <1% | 4,392 | $262K | |
| 62323 | <1% | 502 | $257K | |
| 83970 | <1% | 2,782 | $254K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 1,839 | $254K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,857 | $251K |
| 86803 | <1% | 4,074 | $247K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 252 | $245K |
| 97166 | <1% | 1,778 | $242K | |
| 82040 | <1% | 6,373 | $240K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 2,598 | $237K |
| 73630 | <1% | 3,724 | $237K | |
| 73130 | <1% | 2,468 | $231K | |
| 84439 | <1% | 6,034 | $229K | |
| 70498 | <1% | 915 | $225K | |
| J1815 | Injection, insulin, per 5 units | <1% | 617 | $225K |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 2,077 | $225K |
| 99173 | <1% | 3,433 | $221K | |
| 82247 | <1% | 5,987 | $220K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 242 | $220K |
| 83550 | <1% | 8,913 | $219K | |
| 87040 | <1% | 1,636 | $216K | |
| 72156 | <1% | 193 | $216K | |
| 84155 | <1% | 5,517 | $216K | |
| 84075 | <1% | 5,272 | $215K | |
| 82607 | <1% | 4,580 | $215K | |
| 93226 | <1% | 994 | $212K | |
| 87340 | <1% | 3,180 | $211K | |
| 73590 | <1% | 2,901 | $211K | |
| 72128 | <1% | 1,218 | $206K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,742 | $203K |
| 44970 | <1% | 98 | $203K | |
| 90715 | <1% | 1,418 | $194K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,655 | $194K |
| 73110 | <1% | 2,275 | $193K | |
| 73030 | <1% | 2,564 | $190K | |
| 83540 | <1% | 9,248 | $188K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 2,651 | $188K |
| 87088 | <1% | 2,745 | $187K | |
| 87186 | <1% | 3,354 | $185K | |
| 82330 | <1% | 1,298 | $185K | |
| 82784 | <1% | 4,763 | $183K | |
| 92526 | <1% | 2,110 | $181K | |
| 94760 | <1% | 5,374 | $179K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,911 | $178K |
| 86481 | <1% | 1,566 | $178K | |
| 88304 | <1% | 1,320 | $177K | |
| 83655 | <1% | 8,004 | $175K | |
| 87077 | <1% | 3,671 | $173K | |
| 90870 | <1% | 807 | $172K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,663 | $168K |
| 72100 | <1% | 1,977 | $166K | |
| 77295 | <1% | 74 | $161K | |
| 88342 | <1% | 988 | $160K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 787 | $160K |
| 70486 | <1% | 937 | $159K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 12,862 | $159K |
| 82550 | <1% | 2,824 | $159K | |
| 83615 | <1% | 4,636 | $158K | |
| 72082 | <1% | 1,789 | $156K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,802 | $155K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,325 | $154K |
| 76870 | <1% | 1,114 | $154K | |
| 76642 | <1% | 1,573 | $154K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,185 | $153K |
| 73090 | <1% | 2,004 | $152K | |
| 95816 | <1% | 550 | $152K | |
| 86706 | <1% | 3,006 | $151K | |
| 92588 | <1% | 1,234 | $149K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 731 | $148K |
| 86704 | <1% | 1,846 | $147K | |
| 85379 | <1% | 1,412 | $147K | |
| 93320 | <1% | 1,060 | $145K | |
| 87070 | <1% | 3,623 | $144K | |
| 93017 | <1% | 847 | $143K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 990 | $142K |
| 70496 | <1% | 559 | $139K | |
| 87640 | <1% | 2,433 | $138K | |
| 87641 | <1% | 2,454 | $135K | |
| 99358 | Prolong nursin fac eval 15m | <1% | 1,182 | $134K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,492 | $133K |
| 31575 | <1% | 429 | $133K | |
| 95806 | <1% | 277 | $132K | |
| 74018 | <1% | 2,159 | $132K | |
| 73080 | <1% | 1,685 | $129K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 154 | $128K |
| 86923 | <1% | 720 | $128K | |
| 87205 | <1% | 3,329 | $128K | |
| 97165 | <1% | 1,057 | $126K | |
| 87481 | <1% | 597 | $126K | |
| 99170 | <1% | 641 | $125K | |
| 77290 | <1% | 195 | $124K | |
| 73552 | <1% | 1,733 | $123K | |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 53 | $121K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 598 | $119K |
| 77301 | <1% | 37 | $118K | |
| 72157 | <1% | 109 | $117K | |
| 86003 | <1% | 758 | $114K | |
| 73502 | <1% | 1,398 | $114K | |
| 95886 | <1% | 779 | $112K | |
| 99235 | <1% | 517 | $112K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 771 | $111K |
| 96523 | <1% | 718 | $111K | |
| 93971 | <1% | 722 | $111K | |
| 92567 | <1% | 3,286 | $110K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 613 | $109K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 706 | $107K |
| 87015 | <1% | 889 | $107K | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 25 | $106K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 747 | $106K |
| 80047 | <1% | 576 | $105K | |
| 92610 | <1% | 711 | $104K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 784 | $104K |
| 92557 | <1% | 1,261 | $101K | |
| 94761 | <1% | 216 | $101K | |
| 86708 | <1% | 912 | $99K | |
| 83516 | <1% | 2,681 | $99K | |
| 88341 | <1% | 448 | $99K | |
| 96112 | <1% | 491 | $99K | |
| 96402 | <1% | 476 | $98K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,070 | $98K |
| 72170 | <1% | 1,305 | $97K | |
| 77066 | Tomosynthesis, mammo | <1% | 612 | $94K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,092 | $94K |
| 70491 | <1% | 281 | $93K | |
| 86787 | <1% | 789 | $93K | |
| 73060 | <1% | 962 | $92K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 824 | $91K |
| 85660 | <1% | 911 | $90K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,026 | $90K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 262 | $88K |
| 92579 | <1% | 1,371 | $88K | |
| 72197 | <1% | 88 | $87K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 7,973 | $86K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,856 | $86K |
| 82465 | <1% | 4,630 | $85K | |
| 96900 | <1% | 655 | $85K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 190 | $83K |
| 85014 | <1% | 2,247 | $82K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 560 | $81K |
| 76830 | Ultrasound, transvaginal | <1% | 526 | $81K |
| 87505 | <1% | 539 | $81K | |
| 83718 | <1% | 3,760 | $80K | |
| 82378 | <1% | 894 | $79K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 578 | $78K |
| 20610 | <1% | 339 | $75K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,587 | $74K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 348 | $74K |
| 73100 | <1% | 1,486 | $74K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,843 | $70K |
| 96161 | <1% | 3,076 | $68K | |
| 96409 | <1% | 436 | $68K | |
| 84403 | <1% | 1,149 | $68K | |
| 90686 | <1% | 958 | $68K | |
| 77338 | <1% | 58 | $67K | |
| 76885 | <1% | 654 | $66K | |
| 93271 | <1% | 394 | $66K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 613 | $65K |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 71 | $64K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 458 | $64K |
| 84480 | <1% | 1,251 | $63K | |
| 81415 | <1% | 31 | $63K | |
| A4550 | Surgical trays | <1% | 354 | $61K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 163 | $61K |
| 86038 | <1% | 1,525 | $61K | |
| 85045 | <1% | 4,739 | $60K | |
| 84153 | <1% | 1,512 | $60K | |
| 92551 | <1% | 1,500 | $59K | |
| 87081 | <1% | 214 | $58K | |
| 84165 | <1% | 825 | $58K | |
| 82570 | <1% | 1,676 | $58K | |
| 87522 | Neg quan hep c or qual rna | <1% | 582 | $56K |
| 87507 | <1% | 114 | $56K | |
| 94729 | <1% | 828 | $55K | |
| 82043 | <1% | 4,224 | $55K | |
| 92134 | <1% | 556 | $53K | |
| 72040 | <1% | 1,030 | $52K | |
| J2501 | Injection, paricalcitol, 1 mcg | <1% | 6,169 | $51K |
| 95908 | <1% | 337 | $51K | |
| 84156 | <1% | 1,457 | $49K | |
| 86480 | <1% | 495 | $49K | |
| 94727 | <1% | 825 | $49K | |
| 99221 | <1% | 254 | $49K | |
| 73564 | <1% | 770 | $48K | |
| G0008 | Administration of influenza virus vaccine | <1% | 899 | $47K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,297 | $47K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 142 | $47K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 133 | $46K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 82 | $45K |
| 92585 | <1% | 262 | $45K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 103 | $44K |
| 86618 | <1% | 475 | $44K | |
| 87536 | <1% | 194 | $42K | |
| 96111 | <1% | 375 | $41K | |
| 51701 | <1% | 266 | $41K | |
| 99417 | Prolong home eval add 15m | <1% | 830 | $40K |
| 82977 | <1% | 2,104 | $40K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 179 | $40K |
| 11045 | <1% | 132 | $40K | |
| 95910 | <1% | 160 | $40K | |
| 83001 | <1% | 900 | $39K | |
| 73000 | <1% | 408 | $38K | |
| 82140 | <1% | 270 | $38K | |
| 85018 | <1% | 2,347 | $38K | |
| 87207 | <1% | 244 | $38K | |
| 81514 | <1% | 107 | $36K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 116 | $36K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 320 | $36K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 288 | $35K |
| 83002 | <1% | 829 | $34K | |
| 84702 | <1% | 427 | $34K | |
| 82746 | <1% | 685 | $34K | |
| 82670 | <1% | 588 | $34K | |
| 64645 | <1% | 364 | $33K | |
| 87480 | <1% | 606 | $33K | |
| 87510 | <1% | 606 | $33K | |
| 64646 | <1% | 15 | $33K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 100 | $33K |
| 77072 | <1% | 729 | $33K | |
| 83883 | <1% | 584 | $32K | |
| 80197 | <1% | 1,558 | $32K | |
| 73070 | <1% | 701 | $32K | |
| 76981 | <1% | 265 | $31K | |
| 95819 | <1% | 106 | $31K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 439 | $31K |
| 84402 | <1% | 625 | $31K | |
| 82955 | <1% | 242 | $31K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 210 | $31K |
| 96101 | <1% | 54 | $30K | |
| 87660 | <1% | 602 | $30K | |
| 93321 | <1% | 412 | $29K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 595 | $29K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 424 | $29K |
| 77065 | Tomosynthesis, mammo | <1% | 263 | $29K |
| 87631 | <1% | 149 | $28K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 544 | $28K |
| 95885 | <1% | 393 | $28K | |
| 92611 | <1% | 232 | $28K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 246 | $28K |
| 86360 | <1% | 305 | $26K | |
| 64643 | <1% | 95 | $26K | |
| 82435 | <1% | 189 | $26K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 60 | $26K |
| 72081 | <1% | 480 | $26K | |
| 99174 | <1% | 321 | $26K | |
| 76857 | <1% | 331 | $25K | |
| 84550 | <1% | 1,565 | $25K | |
| 86364 | <1% | 1,119 | $25K | |
| 76882 | <1% | 384 | $25K | |
| 84146 | <1% | 566 | $24K | |
| 88307 | <1% | 162 | $24K | |
| 74019 | <1% | 332 | $24K | |
| 93225 | <1% | 234 | $24K | |
| 82105 | <1% | 626 | $24K | |
| 80177 | <1% | 232 | $24K | |
| 74230 | <1% | 231 | $24K | |
| 88173 | <1% | 197 | $24K | |
| 36591 | <1% | 169 | $23K | |
| 91200 | <1% | 205 | $23K | |
| 95873 | <1% | 181 | $23K | |
| 70544 | <1% | 52 | $21K | |
| 72110 | <1% | 217 | $21K | |
| 82747 | <1% | 446 | $21K | |
| 83921 | <1% | 450 | $21K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 60 | $20K |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 76 | $20K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 17 | $20K |
| 96368 | <1% | 110 | $18K | |
| 86160 | <1% | 329 | $18K | |
| ATP08 | <1% | 2,826 | $18K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 38 | $18K |
| 74174 | <1% | 40 | $18K | |
| 83030 | <1% | 932 | $17K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 34 | $17K |
| 86765 | <1% | 259 | $17K | |
| 86359 | <1% | 304 | $17K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 25 | $16K |
| 0002A | <1% | 716 | $16K | |
| 88185 | <1% | 66 | $16K | |
| 92083 | <1% | 188 | $16K | |
| 97116 | <1% | 178 | $16K | |
| 82272 | <1% | 282 | $15K | |
| 86735 | <1% | 243 | $15K | |
| 89051 | <1% | 115 | $15K | |
| 86334 | <1% | 241 | $15K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 117 | $15K |
| 82139 | <1% | 424 | $15K | |
| 86665 | <1% | 207 | $15K | |
| 95909 | <1% | 83 | $15K | |
| 72070 | <1% | 227 | $15K | |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program | <1% | 215 | $15K |
| 97750 | <1% | 225 | $14K | |
| 86682 | <1% | 108 | $14K | |
| 76506 | <1% | 127 | $14K | |
| 20552 | <1% | 16 | $14K | |
| 0001A | <1% | 769 | $14K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 28 | $14K |
| 90675 | <1% | 55 | $13K | |
| 96160 | <1% | 255 | $13K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 301 | $13K |
| 82150 | <1% | 484 | $13K | |
| 80074 | <1% | 135 | $12K | |
| 80164 | <1% | 171 | $12K | |
| 86147 | <1% | 88 | $12K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 585 | $12K |
| 36593 | <1% | 88 | $12K | |
| 70360 | <1% | 258 | $12K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 39 | $12K |
| 87206 | <1% | 525 | $11K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 313 | $11K |
| 87209 | <1% | 89 | $11K | |
| 83721 | <1% | 530 | $11K | |
| 86762 | <1% | 136 | $11K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 65 | $11K |
| 87075 | <1% | 213 | $11K | |
| 92133 | <1% | 180 | $11K | |
| 87177 | <1% | 89 | $10K | |
| 86141 | <1% | 324 | $10K | |
| 87338 | <1% | 394 | $10K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 172 | $10K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 135 | $10K |
| 92582 | <1% | 233 | $10K | |
| 87799 | <1% | 114 | $10K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 221 | $10K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 42 | $10K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 45 | $10K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 125 | $9K |
| 51798 | <1% | 222 | $9K | |
| 81416 | <1% | 13 | $9K | |
| 82652 | <1% | 118 | $9K | |
| 86235 | <1% | 117 | $9K | |
| ATP15 | <1% | 1,110 | $9K | |
| 83993 | <1% | 268 | $9K | |
| 93042 | <1% | 921 | $8K | |
| 93270 | <1% | 107 | $8K | |
| 83020 | <1% | 219 | $8K | |
| 73562 | <1% | 213 | $8K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 165 | $8K |
| 99223 | Prolong inpt eval add15 m | <1% | 61 | $8K |
| 0124A | <1% | 219 | $8K | |
| 96131 | <1% | 36 | $8K | |
| 82397 | <1% | 220 | $8K | |
| 82533 | <1% | 150 | $7K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 288 | $7K |
| 85240 | <1% | 184 | $7K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 21 | $7K |
| 12011 | <1% | 50 | $7K | |
| 73140 | <1% | 152 | $7K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 163 | $7K |
| 86664 | <1% | 203 | $7K | |
| 83520 | <1% | 209 | $6K | |
| 88184 | <1% | 65 | $6K | |
| 85246 | <1% | 128 | $6K | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 137 | $6K |
| 74241 | <1% | 37 | $6K | |
| 86800 | <1% | 195 | $6K | |
| 73521 | <1% | 128 | $6K | |
| 86146 | <1% | 62 | $6K | |
| ATP07 | <1% | 1,285 | $6K | |
| 86376 | <1% | 193 | $6K | |
| 86039 | <1% | 176 | $6K | |
| 84305 | <1% | 119 | $6K | |
| 77280 | <1% | 26 | $6K | |
| 86663 | <1% | 203 | $6K | |
| 87493 | <1% | 17 | $5K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 374 | $5K |
| 85060 | <1% | 243 | $5K | |
| 92550 | <1% | 195 | $5K | |
| 83021 | <1% | 107 | $5K | |
| 70355 | <1% | 43 | $5K | |
| 64615 | <1% | 26 | $5K | |
| V5011 | Fitting/orientation/checking of hearing aid | <1% | 26 | $5K |
| 90662 | <1% | 317 | $5K | |
| 84466 | <1% | 187 | $5K | |
| 82010 | <1% | 85 | $5K | |
| 82785 | <1% | 133 | $5K | |
| 29125 | <1% | 39 | $5K | |
| 90480 | <1% | 106 | $4K | |
| 81206 | <1% | 19 | $4K | |
| 86592 | <1% | 86 | $4K | |
| 85384 | <1% | 60 | $4K | |
| 72190 | <1% | 64 | $4K | |
| 85245 | <1% | 75 | $4K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 34 | $4K |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 13 | $3K |
| 82787 | <1% | 35 | $3K | |
| 93970 | <1% | 19 | $3K | |
| 91065 | <1% | 22 | $3K | |
| 96380 | <1% | 87 | $3K | |
| 84270 | <1% | 45 | $3K | |
| 87184 | <1% | 93 | $3K | |
| 0031A | <1% | 100 | $3K | |
| 12001 | <1% | 27 | $3K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 17 | $3K |
| 83010 | <1% | 88 | $3K | |
| 82374 | <1% | 61 | $3K | |
| 76937 | <1% | 18 | $3K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 92 | $3K |
| 90714 | <1% | 15 | $2K | |
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 321 | $2K |
| 96130 | <1% | 16 | $2K | |
| 0154A | <1% | 88 | $2K | |
| 0111A | <1% | 96 | $2K | |
| 0250 | <1% | 1,224 | $2K | |
| 83519 | <1% | 70 | $2K | |
| 87147 | <1% | 55 | $2K | |
| 72050 | <1% | 27 | $2K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 29 | $2K |
| 86225 | <1% | 79 | $2K | |
| 86357 | <1% | 49 | $2K | |
| 86355 | <1% | 49 | $2K | |
| 84425 | <1% | 84 | $2K | |
| 86308 | <1% | 38 | $2K | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 76 | $2K |
| 90713 | <1% | 12 | $2K | |
| 84481 | <1% | 51 | $2K | |
| 86580 | <1% | 199 | $2K | |
| 86431 | <1% | 139 | $2K | |
| 74221 | <1% | 14 | $2K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 26 | $2K |
| 73120 | <1% | 22 | $2K | |
| 97016 | <1% | 38 | $2K | |
| 90670 | <1% | 62 | $2K | |
| 99195 | <1% | 19 | $2K | |
| 99443 | <1% | 38 | $2K | |
| V2632 | Posterior chamber intraocular lens | <1% | 21 | $2K |
| 87102 | <1% | 79 | $1K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 70 | $1K |
| T1016 | Case management, each 15 minutes | <1% | 25 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 27 | $1K |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 18 | $1K |
| 97755 | <1% | 14 | $1K | |
| 86753 | <1% | 16 | $1K | |
| 83090 | <1% | 44 | $1K | |
| 83498 | <1% | 13 | $1K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 13 | $1K |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | <1% | 16 | $1K |
| 82525 | <1% | 40 | $986.76 | |
| 84432 | <1% | 29 | $925.64 | |
| 92553 | <1% | 20 | $924.86 | |
| 94664 | <1% | 12 | $912.52 | |
| 88313 | <1% | 15 | $829.07 | |
| 99441 | <1% | 84 | $795.86 | |
| 84478 | <1% | 75 | $781.70 | |
| 90656 | <1% | 14 | $773.96 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 51 | $755.44 |
| 77073 | <1% | 12 | $753.82 | |
| 97542 | <1% | 13 | $741.99 | |
| 82627 | <1% | 12 | $681.83 | |
| 92136 | <1% | 18 | $652.36 | |
| 80230 | <1% | 12 | $622.32 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 20 | $578.23 |
| 76514 | <1% | 28 | $558.27 | |
| 51702 | <1% | 21 | $548.45 | |
| 84134 | <1% | 17 | $538.66 | |
| 87650 | <1% | 15 | $506.55 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 37 | $491.78 |
| 80175 | <1% | 21 | $438.02 | |
| 86902 | <1% | 15 | $411.65 | |
| 88300 | <1% | 35 | $400.05 | |
| J9255 | Injection, methotrexate (accord), not therapeutically equivalent to j9260, 50 mg | <1% | 33 | $328.33 |
| 92593 | <1% | 12 | $321.30 | |
| 80299 | <1% | 12 | $287.32 | |
| 86200 | <1% | 14 | $280.90 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 50 | $279.72 |
| 92025 | <1% | 18 | $278.41 | |
| H2021 | Community-based wrap-around services, per 15 minutes | <1% | 29 | $273.66 |
| 99442 | <1% | 17 | $255.19 | |
| 99406 | <1% | 12 | $228.96 | |
| ATP14 | <1% | 34 | $208.41 | |
| ATP09 | <1% | 33 | $189.46 | |
| 82438 | <1% | 15 | $151.03 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 37 | $133.55 |
| 0003A | <1% | 19 | $25.76 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 13 | $7.04 |
| 90674 | <1% | 15 | $6.52 | |
| 99070 | 0% | 16 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARKELL, PETER (CFO)
Parent organizationLIFESPAN CORPORATION
| Provider | Location | Paid |
|---|---|---|
| The Miriam Hospital | Providence, RI | $138.58M |
| Gateway Healthcare INC | Pawtucket, RI | $122.93M |
| Emma Pendleton Bradley Hospital | Riverside, RI | $37.64M |
| Newport Hospital | Newport, RI | $15.82M |
| Rhode Island Hospital | Providence, RI | $13.22M |
| Lifespan Physician Group, INC. | Warwick, RI | $6.48M |
| Lifespan Physician Group, INC. | Providence, RI | $5.64M |
| Rhode Island Hospital | Providence, RI | $5.32M |
| Emma Pendleton Bradley Hospital | East Providence, RI | $5.03M |
| Lifespan Physician Group INC | Providence, RI | $4.41M |
| Rhode Island Hospital | Providence, RI | $3.97M |
| Newport Hospital | Newport, RI | $3.05M |
| Rhode Island Hospital | East Providence, RI | $2.58M |
| Vna Technicare, INC. | Providence, RI | $2.52M |
| Rhode Island Hospital | Providence, RI | $2.33M |
| Coastal Medical Physicians, INC. | Providence, RI | $1.33M |
| Gateway Healthcare, INC. | Pawtucket, RI | $1.31M |
| Coastal Medical Physicians, INC. | Providence, RI | $1.20M |
| Gateway Healthcare, INC | Johnston, RI | $1.13M |
| Gateway Healthcare, INC | Charlestown, RI | $731K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.